FDA Removes Evusheld’s EUA for COVID-19
AstraZeneca is developing a next-generation long-acting antibody for pre-exposure prophylaxis of COVID-19, which it plans to make available in the second half of 2023.
AstraZeneca’s Evusheld is no longer authorized for use in the United States, according to a notice from the FDA. Evusheld had been granted an emergency use authorization (EUA) in December 2021 for COVID-19 pre-exposure prophylaxis. It is a combination of two long-acting antibodies — tixagevimab and cilgavimab — derived from B-cells donated by convalescent patients after SARS-CoV-2 infection.
Data show Evusheld is unlikely to be active against certain SARS-CoV-2 variants, including the omicron subvariants currently circulating in the United States. According to the most recent CDC modeling data, these variants are projected to be responsible for more than 90% of current infections in the United States. This means that Evusheld is not expected to provide protection against developing COVID-19 if exposed to those variants.
In a statement, AstraZeneca said it will continue to work with the FDA to assess and share relevant data regarding Evusheld and SARS-CoV-2 variants. Evusheld currently remains authorized in other countries where it is approved for COVID-19 pre-exposure prophylaxis and treatment, including the EU and Japan.
The company has initiated the SUPERNOVA program, a phase 1/3 trial to investigate the safety and efficacy of a next-generation long-acting antibody in COVID-19 pre-exposure prophylaxis in an immunocompromised population. In in vitro lab studies, the new long-acting antibody has been shown to neutralize all SARS-CoV-2 variants tested to date, including variants that have proved resistant to other monoclonal antibodies.
AstraZeneca is aiming to make the new long-acting antibody available in the second half of 2023.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
